Nexstim Plc's Financial Information in 2019

Company announcement, Helsinki, 21 December 2018 at 09.00

Nexstim Plc's Financial Information in 2019

Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depression Disorder (MDD), will publish the following financial information in 2019:

The 2018 Financial Statements Release and Half-Yearly Report July-December 2018 (H2) on Friday, March 1, 2019. Half-Yearly Report January-June 2019 (H1) on Friday, August 16, 2019.

Nexstim's Annual Report 2018 will be published on the Company's website on Wednesday, March 6, 2019.

The Annual General Meeting is tentatively scheduled to be held on Wednesday, March 27, 2019 at 10:00 am.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                              

Martin Jamieson, Chairman and CEO

+44 771 516 3942

martin.jamieson@nexstim.com

Sisu Partners Oy (Certified Adviser)

+358 (0)10 231 4560

Citigate Dewe Rogerson            

David Dible/Shabnam Bashir/ Sylvie Berrebi

+44 (0)207 2822949 

david.dible@citigatedewerogerson.com

About Nexstim Plc

Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com.